MALAT1 and neoplasm: Multiple STING agonists, including BI 1703880 and E7766, are currently being investigated in clinical trials (NCT04144140 and NCT05471856) and may emerge as promising approaches.434,435 Additionally, the long noncoding RNA Malat1 has been confirmed to be a critical regulator of tumor initiation and metastatic reactivation in breast cancer models.